Melvin Sharoky
Chairman of The Board
On June 15, 2009, Insmed's Board of Directors appointed Melvin Sharoky, M.D. to assume the role of Chairman of the Board, formerly held by Dr. Geoffrey Allan. Dr. Sharoky has been a member of our Board since May 2001.
From March 2007 to December 2007, he was a consultant with Somerset Pharmaceuticals, a research and development pharmaceutical company which markets Eldepryl for the treatment of patients with late stage Parkinson's disease and developed EMSAM® for major depressive disorder, which is licensed to Bristol-Myers Squibb. From January 2002 until March 2007, he was President and CEO of Somerset Pharmaceuticals, Inc. He previously served as President of Somerset Pharmaceuticals from July 1995 to June 2001. From June 2001 to January 2002, Dr. Sharoky was retired. From July 1995 through January 1998, Dr. Sharoky was President of Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, and from February 1993 to January 1998 he was also President and Chief Executive Officer of its wholly-owned subsidiary, Circa Pharmaceuticals, Inc., which develops, manufactures and markets solid dosage generic pharmaceutical products to wholesale distributors. Dr. Sharoky joined Circa Pharmaceuticals in July 1988 as Medical Director, served as Senior Vice President and Director of Research and Development from April 1991 to August 1992, and as Executive Vice President and Director of Research and Development from August 1992 to January 1993. Prior to this, from February 1986 to June 1988, he was Vice President and Chief Medical Officer of Pharmakinetics Laboratories, Inc.
Dr. Sharoky received a B.A. in Biology from the University of Maryland in Baltimore County and an M.D. from the University of Maryland School of Medicine.
